SCHEDULE 13D/A: Major Shareholder Group Reduces Stake in Stoke Therapeutics Following Share Sale

A group of reporting entities, including Ezbon International Ltd, has reduced its beneficial ownership in Stoke Therapeutics, Inc. to 6% after Ezbon sold 650,000 shares at $11.00 per share.

Summary

• This document is Amendment No. 5 to the Schedule 13D filed by Skorpios Trust, Montrago Trustees Limited, Ezbon International Limited, and Blue Horizon Enterprise Ltd (collectively, the "Reporting Persons") regarding their beneficial ownership in Stoke Therapeutics, Inc.
• On June 18, 2025, Ezbon International Ltd sold 650,000 shares of Stoke Therapeutics, Inc. common stock in an open market transaction.
• The shares were sold at a price of $11.00 per share.
• The percentages of ownership are calculated based on 54,596,924 shares of Stoke Therapeutics' common stock outstanding as of April 30, 2025, as reported in the Company's Form 10-Q filed on May 13, 2025.
• Following the transaction, the beneficial ownership of the Reporting Persons is as follows:
• Blue Horizon Enterprise Ltd beneficially owns 2,967,621 shares, representing 5.4% of the class.
• Ezbon International Ltd beneficially owns 288,560 shares, representing 0.5% of the class.
• Montrago Trustees Ltd beneficially owns 3,256,181 shares, representing 6% of the class.
• Skorpios Trust beneficially owns 3,256,181 shares, representing 6% of the class.
• The aggregate amount beneficially owned by Montrago Trustees Ltd and Skorpios Trust is 3,256,181 shares, representing 6% of the class.

Sentiment

Score: 4

Explanation: The filing reports a significant share sale by one of the reporting entities, reducing their overall stake in the company. While not inherently negative, a reduction in ownership by a large holder can be perceived as a signal of reduced confidence or a strategic shift.

Negatives

• A significant shareholder, Ezbon International Ltd, sold 650,000 shares of Stoke Therapeutics, Inc. common stock.
• This sale reduces the overall beneficial ownership of the reporting group in Stoke Therapeutics, Inc. to 6%.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Stoke Therapeutics, Inc.'s operations or financial performance. It solely reports a past transaction by a beneficial owner.

Industry Context

This filing is an ownership disclosure and does not provide broader industry context or trends for the biotechnology or pharmaceutical sector in which Stoke Therapeutics operates.

Stakeholder Impact

• Shareholders: The sale of a significant block of shares by a large beneficial owner could influence market perception and potentially the stock price due to the increased supply of shares or perceived lack of confidence from a major investor.

Key Dates

Keywords

Stoke Therapeutics, STOK, Schedule 13D, beneficial ownership, share sale, institutional investor, equity, SEC filing